Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Promising new preventative treatment option for population of men at high risk of prostate cancer

20.10.2004


Toremifene study finds significant reduction in the incidence of prostate cancer for men with high grade PIN

Toremifene, a drug currently used to treat breast cancer in women, was found to reduce the incidence of prostate cancer for men at high risk for the disease. In a study presented today at the American Association for Cancer Research Third Annual International Conference on Frontiers in Cancer Prevention Research, scientists found that patients at all dose levels for toremifene had a lower cumulative incidence of cancer after 12 months of treatment, with the 20 mg dose contributing the greatest effect.

All participating patients had high-grade prostatic intraepithelial neoplasia or PIN, characterized by abnormal cells in the lining of the prostate ducts. Early research suggests that most patients with high-grade PIN will develop prostate cancer within 10 years, but more research is needed to confirm those findings.



"For men with high-grade PIN, the prospect of developing prostate cancer is a very real possibility," said Dr. Mitchell S. Steiner, chief executive officer with GTx, Inc. "With no effective treatment options available, doctors and patients often feel defenseless against the onset of prostate cancer. "Fortunately, these results offer a promising new preventive approach to prostate cancer treatment. A chemopreventive agent like toremifene is a first step toward the possibility of stopping prostate cancer before it starts and gives patients and doctors a chance to fight this pervasive disease."

In a multi-center, double-blind study, 514 patients with high-grade PIN and no cancer, determined by pre-study biopsies, were randomized to placebo or toremifene 20 mg, 40 mg or 60 mg given orally once a day. Patients were re-biopsied at six and 12 months.

During the study, 24.4 percent of patients taking 20 mg dose of toremifene were diagnosed with prostate cancer versus 31.2 percent of patients taking placebo. Among the patients who completed 12 months of treatment, the reduction in prostate cancer incidence was 48 percent for patients receiving 20 mg of toremifene compared to those in the placebo group.

According to the National Cancer Institute, prostate cancer is the most commonly diagnosed cancer in America among men. With an estimated 220,000 new cases diagnosed each year, one in every five men will get prostate cancer during his lifetime. African-American men are at special risk for the disease. In fact, the incidence rate in African-Americans is 60 percent higher than that in white males and double the mortality rate. An estimated 29,900 American men lose their lives to prostate cancer each year.

Warren Froelich | EurekAlert!
Further information:
http://www.aacr.org

More articles from Health and Medicine:

nachricht Tracking movement of immune cells identifies key first steps in inflammatory arthritis
23.01.2017 | Massachusetts General Hospital

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Quantum optical sensor for the first time tested in space – with a laser system from Berlin

For the first time ever, a cloud of ultra-cold atoms has been successfully created in space on board of a sounding rocket. The MAIUS mission demonstrates that quantum optical sensors can be operated even in harsh environments like space – a prerequi-site for finding answers to the most challenging questions of fundamental physics and an important innovation driver for everyday applications.

According to Albert Einstein's Equivalence Principle, all bodies are accelerated at the same rate by the Earth's gravity, regardless of their properties. This...

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Tracking movement of immune cells identifies key first steps in inflammatory arthritis

23.01.2017 | Health and Medicine

Electrocatalysis can advance green transition

23.01.2017 | Physics and Astronomy

New technology for mass-production of complex molded composite components

23.01.2017 | Process Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>